# Mojia (Shanghai) Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mojia-shanghai-biotechnology-co

- Industry: Food
- Headquarters: Shanghai, China
- Website: www.mojiabio.com
- Total disclosed funding: $94M
- Latest round: Series B (Jun 23, 2022)
- Investors on record: 5

## About

Founded in 2018 and based in Shanghai, China, Mojia (Shanghai) Biotechnology Co., Ltd. operates as a green biomanufacturing solutions provider, dedicated to developing green biomanufacturing methods. In August 2020, the company raised CNY 100 million in series A funding from new investors Bits x Bites and Asia Green Fund. The company's vitamin B5 product achieved mass production in June 2022.

The company uses renewable carbon sources and green processes to enable the production of food additives and chemical products. The company also transforms its platform based on its innovative enzyme engineering and biometabolism technologies. The company's main products are Viridimin® series of vitamin B5 products and Aliphane® series of bio-based polymer products. The Aliphane® family of bio-based polymers can be used in coatings and adhesives.

The company will focus on the industrialization and commercialization of its core bio-based products, as well as the development of new product pipelines and team expansion.

## Funding rounds

- Series B, Jun 23, 2022, $80M — Temasek Holdings, LYZZ Capital, Asia Green Fund, Bits x Bites, Sento Investment
- Series A, Aug 20, 2020, $14M — Asia Green Fund, Bits x Bites

## Investors

- Asia Green Fund (https://capitalatlas.ai/funds/asia-green-fund) — Series A, Series B
- Bits x Bites (https://capitalatlas.ai/funds/bits-x-bites) — Series A, Series B
- Temasek Holdings — Series B
- LYZZ Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series B
- Sento Investment — Series B